Oxeia named a One Nucleus finalist for annual BioNewsRound Award for the company’s announcement of the initiation of Phase 2 trial for its drug treatment for concussion, OXE103. The award, which recognizes life science companies with exciting developments, will be announced at the annual Genesis conference on December 10, 2020.
Drug Discovery News: One Nucleus announces life science award shortlist
Previous
Previous
The Sports Column: COVID Didn’t Bench NFL Football, But Head Injuries/ Concussions Could
Next
Next